Chromosome arm 8p and cancer: a fragile hypothesis. 2003

Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
Department of Molecular Oncology, Institut Paoli-Calmettes and U119 Inserm, IFR57, Marseille, France. birnbaum@marseille.inserm.fr

Chromosome arm 8p is one of the most frequently altered regions in human cancers. Several potential oncogenes and tumour suppressor genes have been identified but further investigations are needed to confirm which are bona fide oncogenic targets. In cancer cells, chromosome breaks may occur at fragile sites throughout the genome. Some fragile sites lie within genes that may have a role in cancer; the best example is FHIT at 3p14, which contains the fragile site FRA3B. We have found that chromosome breaks disrupt the NRG1 gene at 8p12 in breast and pancreatic cancers. We hypothesise that alteration of the NRG1 gene could occur through breakage at a non-common fragile site.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002873 Chromosome Fragility Susceptibility of chromosomes to breakage leading to translocation; CHROMOSOME INVERSION; SEQUENCE DELETION; or other CHROMOSOME BREAKAGE related aberrations. Chromosomal Fragility,Fragility, Chromosomal,Fragility, Chromosome
D002898 Chromosomes, Human, Pair 8 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 8
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017766 Acid Anhydride Hydrolases A group of enzymes that catalyze the hydrolysis of diphosphate bonds in compounds such as nucleoside di- and tri-phosphates, and sulfonyl-containing anhydrides such as adenylylsulfate. (Enzyme Nomenclature, 1992) EC 3.6. Anhydride Hydrolases, Acid,Hydrolases, Acid Anhydride
D043283 Chromosome Fragile Sites Specific loci that show up during KARYOTYPING as a gap (an uncondensed stretch in closer views) on a CHROMATID arm after culturing cells under specific conditions. These sites are associated with an increase in CHROMOSOME FRAGILITY. They are classified as common or rare, and by the specific culture conditions under which they develop. Fragile site loci are named by the letters "FRA" followed by a designation for the specific chromosome, and a letter which refers to which fragile site of that chromosome (e.g. FRAXA refers to fragile site A on the X chromosome. It is a rare, folic acid-sensitive fragile site associated with FRAGILE X SYNDROME.) Fragile Sites, Chromosome,Chromosome Fragile Site,Fragile Site, Chromosome,Site, Chromosome Fragile,Sites, Chromosome Fragile
D019457 Chromosome Breakage A type of chromosomal aberration involving DNA BREAKS. Chromosome breakage can result in CHROMOSOMAL TRANSLOCATION; CHROMOSOME INVERSION; or SEQUENCE DELETION. Chromosomal Breakage,Chromosomal Breaks,Chromosome Breaks,Break, Chromosomal,Break, Chromosome,Breakage, Chromosomal,Breakage, Chromosome,Breakages, Chromosomal,Breakages, Chromosome,Breaks, Chromosomal,Breaks, Chromosome,Chromosomal Break,Chromosomal Breakages,Chromosome Break,Chromosome Breakages

Related Publications

Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
April 1979, Human genetics,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
July 1994, Genes, chromosomes & cancer,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
July 1996, Genes, chromosomes & cancer,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
February 2004, The Lancet. Oncology,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
January 2001, Cancer genetics and cytogenetics,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
July 1999, Gynecologic oncology,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
July 2010, Genes, chromosomes & cancer,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
March 1998, The American journal of pathology,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
July 2005, Cancer genetics and cytogenetics,
Daniel Birnbaum, and José Adélaïde, and Cornel Popovici, and Emmanuelle Charafe-Jauffret, and Marie-Joelle Mozziconacci, and Max Chaffanet
March 1988, Cancer genetics and cytogenetics,
Copied contents to your clipboard!